Bristol-Myers Squibb Company
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Christopher S. Boerner
- Full Time Employees
- 34,100
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Address
- Route 206 & Province Line Road Princeton NJ United States of America 08543
- IPO Date
- Jun 1, 1972
- CIK
- 0000014272
- Website
- bms.com
- Similar Companies
- Business
- Bristol-Myers Squibb Company (NYSE: BMY), a global biopharmaceutical company headquartered in Princeton, New Jersey with roots tracing to mergers of entities founded in 1858 and 1887, discovers, develops, manufactures, and commercializes innovative medicines for serious diseases including cancer, immunology, cardiovascular, hematology, and neuroscience disorders; its primary products include the anticoagulant Eliquis (apixaban), oncology therapies such as Opdivo (nivolumab), Yervoy, Krazati, and Revlimid (lenalidomide), cell therapies Abecma and Breyanzi, immunomodulators like Orencia and Pomalyst, legacy brands such as Abraxane, Camzyos for hypertrophic cardiomyopathy, Cobenfy in neuroscience, and others including Baraclude, IDHIFA, Inrebic, Nulojix, Opdivo Qvantig, Reblozyl, and Thalidomid; the company operates in more than 120 countries with a focus on oncology, hematology, immunology, cardiovascular, and fibrotic diseases targeting patients with high unmet needs. In recent developments, Bristol-Myers Squibb completes the acquisition of Orbital Therapeutics in 2025 to strengthen its cell therapy portfolio with RNA medicines reprogramming the immune system; it forms a joint venture with Bain Capital in July 2025 for innovative immunology therapies and enters a global strategic partnership with BioNTech in June 2025 to co-develop and co-commercialize next-generation bispecific antibody BNT327 for multiple solid tumors; earlier, the company acquires 2seventy bio in March 2025 for full control of Abecma amid competitive pressures, completes acquisitions of Karuna Therapeutics in March 2024 to bolster neuroscience, RayzeBio in February 2024 for actinium-based radiopharmaceuticals, and Mirati Therapeutics in January 2024 to diversify oncology, alongside a $380 million capacity agreement with Cellares in April 2024 for CAR T manufacturing.
Bristol Myers Squibb: Pain First, Payoff Later?
Bristol-Myers Squibb: Cash Flow Machine, Outsized Growth Portfolio, And Inflation Beating Incomes
Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It
Bristol Myers Squibb vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?
Why Bristol Myers Squibb (BMY) is a Top Value Stock for the Long-Term
Merck, AbbVie probed by US lawmakers over China clinical trials: report
Recursion Pharmaceuticals vs. Summit Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?
Bristol Myers Squibb (BMY) Exceeds Market Returns: Some Facts to Consider
66 With $1.3 Million. Here Are 3 Hidden Gems to Target
Here's Why Bristol Myers Squibb (BMY) is a Strong Momentum Stock
Bristol Myers Squibb vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?
Revisiting Stock Picks Intel, Progressive, Bristol Myers Squibb
Bristol Myers Squibb (BMY) Ascends While Market Falls: Some Facts to Note
3 Reasons to Buy Bristol Myers Squibb Stock
Bristol Myers Squibb to Report Results for Second Quarter 2026 on July 30, 2026
Bristol Myers Squibb Announces Dividend
Elicio Therapeutics Points To Durable Responses As It Maps Next Steps For Lead Cancer Drug
The Healthcare M&A Wave
3 Stocks to Invest In to Rebalance Your Portfolio
Investors Heavily Search Bristol Myers Squibb Company (BMY): Here is What You Need to Know